PHILADELPHIA – Labor induction is one of the most common medical procedures in the world, with nearly one-quarter of women who deliver in the U.S. undergoing the procedure each year (totaling roughly 1 million). Despite its widespread use, labor induction is costly and still has no widely accepted “best practice.” Now, new research from the Perelman School of Medicine at the University of Pennsylvania is showing what may be the best available method for inducing labor, which may be necessary under circumstances including medical conditions such as preeclampsia, gestational diabetes or other health risks to the mom or baby.
In the largest-ever clinical trial of labor induction methods, researchers found that on average, the use of the prostaglandin-like drug misoprostol, along with a balloon catheter known as the Foley catheter that is inserted into the vagina and gently coaxes the cervix to open, led to delivery several hours earlier than either method alone, or via the combination of the Foley catheter and the contraction-inducing hormone oxytocin. The results are published in the December issue of Obstetrics & Gynecology.
“Previous studies comparing labor-induction methods, have looked at a small patient population, few induction methods, and have produced conflicting results. Our results clearly show that the misoprostol-Foley combination method could significantly reduce the total time mothers spend in the delivery room – potentially leading to a reduction in labor-associated healthcare costs and risks to mothers and their babies,“ said lead author Lisa D. Levine, MD, MSCE, an assistant professor of Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania.
In the study, the research team enrolled nearly 500 women who needed labor induction at the Hospital of the University of Pennsylvania, and randomly assigned them to one of four different treatments that obstetricians commonly use to induce labor: misoprostol alone, the Foley catheter method alone, the two methods combined, and the Foley method plus a synthetic version of the hormone oxytocin.
Results show the average time between treatment and delivery was lowest for the misoprostol-Foley combination at 13.1 hours, compared to 14.5 hours for Foley-oxytocin, 17.6 hours for misoprostol alone, and 17.7 hours for the Foley method alone.
Levine says the more than four-hour gap between misoprostol-Foley and either method alone is clinically meaningful, particularly considering the results showed the various methods did not produce significant differences in the rates of cesarean deliveries or of serious medical complications for the mother or child.
The findings have a clear clinical implication. “Using combination methods in every case of labor induction in America would spare pregnant women more than 100,000 days of labor annually,” Levine said. “That in turn would reduce hospital costs, reduce the health risks to mother and child that come with prolonged labor, and reduce the stress that mothers experience while awaiting delivery.”
The research team suggests future studies examining the combination vs. single methods in other large patient populations would enable more detailed comparisons of health outcomes for mother and baby with different induction methods.
Co-authors were Katheryne L. Downes, Michal A. Elovitz, Samuel Parry, Mary D. Sammel and Sindhu K. Srinivas, all of Penn Medicine.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.